BOUT - ETF AI Analysis
Top Page
Innovator IBD Breakout Opportunities ETF (BOUT)
Rating:64Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in recent months, suggesting its breakout strategy has been working recently.
Strong Top Holdings Momentum
Many of the top holdings have delivered strong year-to-date gains, which has helped drive the fund’s overall performance.
Sector Diversification
The fund spreads its investments across several sectors like financials, industrials, technology, and materials, which can help reduce the impact if one industry struggles.
Negative Factors
High Expense Ratio
The ETF charges a relatively high fee, which can eat into returns over time compared with lower-cost funds.
Small Asset Base
With a relatively low amount of money invested in the fund, it may be less liquid and more vulnerable to large investor moves than bigger ETFs.
Heavy U.S. Concentration
The portfolio is invested almost entirely in U.S. stocks, offering very limited geographic diversification outside the United States.
BOUT vs. SPDR S&P 500 ETF (SPY)
AUM16.31M
RegionNorth America
Expense Ratio0.80%
Beta0.93
IssuerCapForce
Inception DateSep 13, 2018
Dividend Yield0.27%
Asset ClassEquity
Index TrackedIBD Breakout Stocks Total Return
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,036
30 Day Avg. Volume2,374
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
51.48Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering26
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BOUT Summary
The Innovator IBD Breakout Opportunities ETF (BOUT) follows the IBD Breakout Stocks Total Return index, focusing on U.S. companies that Investor’s Business Daily believes are ready for strong price moves. It holds a mix of financial, industrial, technology, and other stocks, including well-known names like Interactive Brokers and Iron Mountain. Someone might invest in BOUT to seek growth and to spread their money across many different sectors instead of picking individual stocks. A key risk is that these “breakout” stocks can be very volatile, so the ETF’s price can rise and fall quickly with market swings.
How much will it cost me?The Innovator IBD Breakout Opportunities ETF (BOUT) has an expense ratio of 0.85%, which means you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on identifying breakout opportunities in the market rather than passively tracking an index.
What would affect this ETF?The Innovator IBD Breakout Opportunities ETF (BOUT), with its focus on U.S. growth-oriented stocks in sectors like technology and industrials, could benefit from advancements in innovation and increased corporate spending in these areas. However, rising interest rates or economic slowdowns could negatively impact growth-focused companies, especially in sectors like technology and healthcare, which are sensitive to changes in borrowing costs and consumer demand.
BOUT Top 10 Holdings
BOUT is leaning heavily into U.S. financials, with names like Interactive Brokers and Goldman Sachs doing much of the heavy lifting as their shares have been steadily rising. US Bancorp is also pulling its weight, though its momentum looks a bit more measured. On the flip side, Truist Financial is more of a flat tire, not really keeping up with the rest of the pack. Outside of banks, Corning and Iron Mountain add a tech-and-infrastructure flavor, both trending higher and helping diversify what is otherwise a very finance-centric, U.S.-focused breakout portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| US Bancorp | 7.12% | $1.17M | $98.36B | 37.92% | 76 Outperform | |
| Apogee Therapeutics | 6.96% | $1.14M | $10.10B | 243.01% | 49 Neutral | |
| Enliven Therapeutics | 6.91% | $1.13M | $3.80B | 136.26% | 36 Underperform | |
| Mirum Pharmaceuticals | 6.67% | $1.09M | $7.25B | 124.48% | 56 Neutral | |
| Bicara Therapeutics Inc. | 6.63% | $1.09M | $1.82B | 141.55% | 48 Neutral | |
| Goldman Sachs Group | 6.17% | $1.01M | $314.25B | 49.44% | 73 Outperform | |
| Bank of America | 6.13% | $1.01M | $434.81B | 27.25% | 72 Outperform | |
| UBS Group AG | 6.11% | $1.00M | $158.96B | 41.87% | 73 Outperform | |
| PNC Financial | 6.04% | $989.67K | $100.89B | 27.60% | 71 Outperform | |
| Parker Hannifin | 5.93% | $972.72K | $120.19B | 33.68% | 79 Outperform |
BOUT Technical Analysis
Neutral
―
Price Trends
46.89
Negative
44.09
Positive
41.11
Positive
Market Momentum
-0.14
Positive
43.68
Neutral
33.86
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BOUT, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 47.36, equal to the 50-day MA of 46.89, and equal to the 200-day MA of 41.11, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 43.68 is Neutral, neither overbought nor oversold. The STOCH value of 33.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BOUT.
BOUT Peer Comparison
Comparison Results
Performance Comparison
BOUT
Innovator IBD Breakout Opportunities ETF
46.68
8.96
23.75%
BAMD
Brookstone Dividend Stock ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
BUZZ
VanEck Social Sentiment ETF
―
―
―
ABLD
Abacus FCF Real Assets Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents